Cited by 163Protein Kinase Regulation and GTPase SignalingProtein Tyrosine PhosphatasesMelanoma and MAPK Pathways

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors

Hansen, Rasmus, Peters, Ulf, Babbar, Anjali, Chen, Yuching, Feng, Jun, Janes, Matthew R., Li, Lian-Sheng, Ren, Pingda, Liu, Yi, Zarrinkar, Patrick P.·2018·Nature Structural & Molecular Biology

DOI 10.1038/s41594-018-0061-5

Open this paper in CoChat — free account

Abstract

Activating mutations in KRAS are among the most common tumor driver mutations. Until recently, KRAS had been considered undruggable with small molecules; the discovery of the covalent KRAS G12C inhibitors ARS-853 and ARS-1620 has demonstrated that it is feasible to inhibit KRAS with high potency in cells and animals. Although the biological activity of these inhibitors has been described, the biochemical mechanism of how the compounds achieve potent inhibition remained incompletely understood. We now show that the activity of ARS-853 and ARS-1620 is primarily driven by KRAS-mediated catalysis of the chemical reaction with Cys12 in human KRAS G12C, while the reversible binding affinity is weak, in the hundreds of micromolar or higher range. The mechanism resolves how an induced, shallow and dynamic pocket not expected to support high-affinity binding of small molecules can nevertheless be targeted with potent inhibitors and may be applicable to other targets conventionally considered undruggable.

Integrity signals

Registry

Crossref · 10.1038/s41594-018-0061-5

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold
Walker, J. E., Saraste, M., Runswick, M. J., & Gay, N. J. (1982) · The EMBO Journal · doi:10.1002/j.1460-2075.1982.tb01276.x · Cited by 5,312
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,354
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Self-citation
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
Self-citation
Refined crystal structure of the triphosphate conformation of H‐ras p21 at 1.35 A resolution: implications for the mechanism of GTP hydrolysis.
PAI, E. F., Krengel, U., Petsko, G. A., Goody, R. S., Kabsch, W., & Wittinghofer, A. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07409.x · Cited by 1,073

Show all 39 references

Research works printed but not linked: 1

Patricelli, M. P., Peters, U., Li, L., Ren, P. & Liu, Y. Method for screening inhibitors of Ras. US Patent 9, 810690 (2017).

Sorted by citations

The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor
Wang, X., Allen, S., Blake, J. F., Bowcut, V., Briere, D. M., Calinisan, A., Dahlke, J. R., Fell, J. B., Fischer, J. P., Gunn, R. J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01688 · Cited by 769
Identification of the Clinical Development Candidate MRTX849 , a Covalent KRASG12C Inhibitor for the Treatment of Cancer
Fell, J. B., Fischer, J. P., Baer, B. R., Blake, J. F., Bouhana, K., Briere, D. M., Brown, K. D., Burgess, L. E., Burns, A. C., Burkard, M. R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02052 · Cited by 653
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Roskoski, R. J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.039 · Cited by 314
The current understanding of KRAS protein structure and dynamics
Pantsar, T. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.12.004 · Cited by 304
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
Fedele, C., Li, S., Teng, K. W., Foster, C. J. R., Peng, D., Ran, H., Mita, P., Geer, M. J., Hattori, T., Koide, A., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201414 · Cited by 265
Covalent Inhibition in Drug Discovery
Ghosh, A. K., Samanta, I., Mondal, A., & Liu, W. R. (2019) · ChemMedChem · doi:10.1002/cmdc.201900107 · Cited by 265
Emerging strategies to target RAS signaling in human cancer therapy
Chen, K., Zhang, Y., Qian, L. M., & Wang, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01127-w · Cited by 247
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
Roskoski, R. J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.013 · Cited by 199
Overview of Recent Strategic Advances in Medicinal Chemistry
Wu, G., Zhao, T., Kang, D., Zhang, J., Song, Y., Namasivayam, V., Kongsted, J., Pannecouque, C. C., Clercq, E. D., Poongavanam, V., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00359 · Cited by 184
Chemoselective Covalent Modification of K-Ras(G12R) with a Small Molecule Electrophile
Zhang, Z., Morstein, J., Ecker, A. K., Guiley, K. Z., & Shokat, K. M. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c05377 · Cited by 159
KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge
Mao, Z., Xiao, H., Shen, P., Yang, Y., Xue, J., Yang, Y., Shang, Y., Zhang, L., Li, X., Zhang, Y., et al. (2022) · Cell Discovery · doi:10.1038/s41421-021-00368-w · Cited by 158
Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S)
Zhang, Z., Guiley, K. Z., & Shokat, K. M. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01065-9 · Cited by 153
Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
Baltgalvis, K. A., Lamb, K. N., Symons, K. T., Wu, C.-C., Hoffman, M. A., Snead, A. N., Song, X., Glaza, T., Kikuchi, S., Green, J. C., et al. (2024) · Nature · doi:10.1038/s41586-024-07318-y · Cited by 134
Characterising covalent warhead reactivity
Martin, J. S., Mackenzie, C. J., Fletcher, D., & Gilbert, I. H. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.04.002 · Cited by 129
10 Years Into the Resurgence of Covalent Drugs
Vita, E. D. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0236 · Cited by 125
KRasG12C inhibitors in clinical trials: a short historical perspective
Goebel, L., Müller, M. P., Goody, R. S., & Rauh, D. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00096e · Cited by 135
GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf
Zhang, Z., Gao, R., Hu, Q., Peacock, H., Peacock, D. M., Dai, S., Shokat, K. M., & Suga, H. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00514 · Cited by 124
A Comprehensive Guide for Assessing Covalent Inhibition in Enzymatic Assays Illustrated with Kinetic Simulations
Mons, E., Roet, S., Kim, R. Q., & Mulder, M. P. C. (2022) · Current Protocols · doi:10.1002/cpz1.419 · Cited by 125
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations
König, D., Prince, S. S., & Rothschild, S. I. (2021) · Cancers · doi:10.3390/cancers13040804 · Cited by 119
KRAS is vulnerable to reversible switch-II pocket engagement in cells
Vasta, J. D., Peacock, D. M., Zheng, Q., Walker, J. A., Zhang, Z., Zimprich, C. A., Thomas, M. R., Beck, M. T., Binkowski, B. F., Corona, C. R., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-00985-w · Cited by 115
Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes
Hartung, I. V., Rudolph, J., Mader, M. M., Mulder, M. P. C., & Workman, P. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00550 · Cited by 105
A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability
Guiley, K. Z., & Shokat, K. M. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0381 · Cited by 102
Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics
Chen, H., Smaill, J. B., Liu, T., Ding, K., & Lu, X. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01312 · Cited by 104
Covalent Small Molecules as Enabling Platforms for Drug Discovery
Dalton, S. E., & Campos, S. (2019) · ChemBioChem · doi:10.1002/cbic.201900674 · Cited by 101
Covalent inhibition of NSD1 histone methyltransferase
Huang, H., Howard, C. A., Zari, S., Cho, H. J., Shukla, S., Li, H., Ndoj, J., Gónzález-Alonso, P., Nikolaidis, C., Abbott, J. M., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0626-6 · Cited by 94
Drugging “undruggable” genes for cancer treatment: Are we making progress?
Duffy, M. J., & Crown, J. P. (2020) · International Journal of Cancer · doi:10.1002/ijc.33197 · Cited by 86
Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRASG12C
Kettle, J. G., Bagal, S. K., Bickerton, S., Bodnarchuk, M. S., Breed, J., Carbajo, R. J., Cassar, D. J., Chakraborty, A., Cosulich, S. C., Cumming, I. A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01720 · Cited by 84
Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D
Zheng, Q., Zhang, Z., Guiley, K. Z., & Shokat, K. M. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01565-w · Cited by 80
Quantifying the Interactions between Biomolecules: Guidelines for Assay Design and Data Analysis
Tonge, P. J. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00012 · Cited by 80
Drugging K-RasG12C through covalent inhibitors: Mission possible?
Ni, D., Li, X., He, X., Zhang, H., Zhang, J., & Lu, S. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.007 · Cited by 73
The Function of RAS Mutation in Cancer and Advances in its Drug Research
Chen, S., Li, F., Xu, D., Hou, K., Fang, W., & Li, Y. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190506122228 · Cited by 75
Bifunctional Small‐Molecule Ligands of K‐Ras Induce Its Association with Immunophilin Proteins
Zhang, Z., & Shokat, K. M. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201910124 · Cited by 66
Progress in targeting RAS with small molecule drugs
McCormick, F. P. (2019) · Biochemical Journal · doi:10.1042/bcj20170441 · Cited by 64
Mutant KRAS Drives Immune Evasion by Sensitizing Cytotoxic T‐Cells to Activation‐Induced Cell Death in Colorectal Cancer
Liu, H., Liang, Z., Cheng, S., Huang, L., Li, W., Zhou, C., Zheng, X., Li, S., Zeng, Z., & Kang, L. (2023) · Advanced Science · doi:10.1002/advs.202203757 · Cited by 60
Kinetic Optimization of Lysine-Targeting Covalent Inhibitors of HSP72
Pettinger, J., Carter, M., Jones, K., & Cheeseman, M. D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01709 · Cited by 59
Sticking it to KRAS: Covalent Inhibitors Enter the Clinic
McCormick, F. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.009 · Cited by 56
A guide to enzyme kinetics in early drug discovery
Srinivasan, B. (2022) · FEBS Journal · doi:10.1111/febs.16404 · Cited by 52
More to the RAS Story: KRAS G12C Inhibition, Resistance Mechanisms, and Moving Beyond KRAS G12C
Lietman, C. D., Johnson, M. L., McCormick, F., & Lindsay, C. R. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351333 · Cited by 44
High-Throughput Kinetic Characterization of Irreversible Covalent Inhibitors of KRAS G12C by Intact Protein MS and Targeted MRM
Li, K. S., Quinn, J. G., Saabye, M. J., Guerrero, J. F. S., Nonomiya, J., Lian, Q., Phung, W., Izrayelit, Y., Walters, B. T., Gustafson, A. E., et al. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c04463 · Cited by 45
Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection
Ge, R., Shen, Z., Yin, J., Chen, W., Zhang, Q., An, Y., Tang, D., Satz, A. L., Su, W., & Kuai, L. (2022) · SLAS DISCOVERY · doi:10.1016/j.slasd.2022.01.001 · Cited by 43
Drugging the Next Undruggable KRAS Allele-Gly12Asp
Zheng, Q., Peacock, D. M., & Shokat, K. M. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00099 · Cited by 41
Systematic Studies on the Protocol and Criteria for Selecting a Covalent Docking Tool
Wen, C., Yan, X., Gu, Q., Du, J., Wu, D., Lu, Y., Zhou, H., & Xu, J. (2019) · Molecules · doi:10.3390/molecules24112183 · Cited by 37
Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
Nollmann, F. I., & Ruess, D. A. (2020) · Biomedicines · doi:10.3390/biomedicines8080281 · Cited by 33
Targeting KRAS in PDAC: A New Way to Cure It?
He, Q., Liu, Z., & Wang, J. (2022) · Cancers · doi:10.3390/cancers14204982 · Cited by 39
A practical guide for the assay-dependent characterisation of irreversible inhibitors
Mader, L. K., Borean, J. E., & Keillor, J. W. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00707g · Cited by 31
Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRASG12C
Mortier, J., Friberg, A., Badock, V., Moosmayer, D., Schroeder, J., Steigemann, P., Siegel, F., Gradl, S., Bauser, M., Hillig, R. C., et al. (2020) · ChemMedChem · doi:10.1002/cmdc.201900727 · Cited by 29
Anaphylaxis to drugs: Overcoming mast cell unresponsiveness by fake antigens
Pichler, W. J. (2020) · Allergy · doi:10.1111/all.14554 · Cited by 29
Synthesis, Docking, Computational Studies, and Antimicrobial Evaluations of New Dipeptide Derivatives Based on Nicotinoylglycylglycine Hydrazide
Khalaf, H. S., Naglah, A. M., Al-Omar, M. A., Moustafa, G. O., Awad, H. M., & Bakheit, A. H. H. (2020) · Molecules · doi:10.3390/molecules25163589 · Cited by 30
Inhibition of thrombin activity by a covalent-binding aptamer and reversal by the complementary strand antidote
Tabuchi, Y., Yang, J., & Taki, M. (2021) · Chemical Communications · doi:10.1039/d0cc08109d · Cited by 31
Structure-based inhibitor design of mutant RAS proteins—a paradigm shift
Nyíri, K., Koppány, G., & Vértessy, B. G. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09914-6 · Cited by 27
The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair Pathways
Cáceres-Gutiérrez, R. E., Alfaro‐Mora, Y., Andonegui, M. A., Díaz‐Chávez, J., & Herrera, L. A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.751367 · Cited by 28
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen
Wright, K. M., DiNapoli, S. R., Miller, M. S., Azurmendi, P. A., Zhao, X., Yu, Z., Chakrabarti, M., Shi, W., Douglass, J., Hwang, M. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40821-w · Cited by 29
Proof of concept for poor inhibitor binding and efficient formation of covalent adducts of KRAS G12C and ARS compounds
Khrenova, M. G., Kulakova, A. M., & Nemukhin, A. V. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob00071j · Cited by 26
Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead
Li, H., Qi, W.-L., Wang, Y., & Meng, L. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.011 · Cited by 28
Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy
Kirschner, T., Müller, M. P., & Rauh, D. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02403 · Cited by 23
Unveiling the “invisible” druggable conformations of GDP-bound inactive Ras
Liu, D., Mao, Y., Gu, X., Zhou, Y., & Long, D. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2024725118 · Cited by 22
Covalent inhibitors of the GTPase KRASG12C: a review of the patent literature
Kettle, J. G., & Cassar, D. J. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1709443 · Cited by 23
Discovery of covalent enzyme inhibitors using virtual docking of covalent fragments
Chowdhury, S. R., Kennedy, S., Zhu, K., Mishra, R. K., Chuong, P., Nguyen, A.-U., Kathman, S. G., & Statsyuk, A. V. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.11.019 · Cited by 23
Precedence and Promise of Covalent Inhibitors of EGFR and KRAS for Patients with Non-Small-Cell Lung Cancer
Cheng, H., & Planken, S. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00311 · Cited by 23
Technologies for Direct Detection of Covalent Protein–Drug Adducts
Mons, E., Kim, R. Q., & Mulder, M. P. C. (2023) · Pharmaceuticals · doi:10.3390/ph16040547 · Cited by 23
Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds?
Tao, H., Yang, B., Farhangian, A., Xu, K., Li, T., Zhang, Z., & Li, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02760 · Cited by 21
Biophysical and structural analysis of KRAS switch-II pocket inhibitors reveals allele-specific binding constraints
Alexander, P., Chan, A. H., Rabara, D., Swain, M., Larsen, E. K., Dyba, M. D., Chertov, O., Ashraf, M., Champagne, A., Lin, K. Y., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110331 · Cited by 24
Oncogenic KRAS G12C: Kinetic and redox characterization of covalent inhibition
Huynh, M. V., Parsonage, D., Forshaw, T. E., Chirasani, V. R., Hobbs, G. A., Wu, H., Lee, J., Furdui, C. M., Poole, L. B., & Campbell, S. L. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102186 · Cited by 21
KRAS Ubiquitination at Lysine 104 Retains Exchange Factor Regulation by Dynamically Modulating the Conformation of the Interface
Yin, G., Zhang, J., Nair, V. V., Truong, V. H., Chaia, A. I., Petela, J., Harrison, J. S., Gorfe, A. A., & Campbell, S. L. (2020) · iScience · doi:10.1016/j.isci.2020.101448 · Cited by 21
Multiparameter Kinetic Analysis for Covalent Fragment Optimization by Using Quantitative Irreversible Tethering (qIT)
Craven, G. B., Affron, D. P., Kösel, T., Wong, T. L., Jukes, Z., Liu, C., Morgan, R. M. L., Armstrong, A., & Mann, D. J. (2020) · ChemBioChem · doi:10.1002/cbic.202000457 · Cited by 20
Inhibition of RAS: proven and potential vulnerabilities
Zuberi, M., Khan, I., & O’Bryan, J. P. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190023 · Cited by 20
Binding modes of GDP, GTP and GNP to NRAS deciphered by using Gaussian accelerated molecular dynamics simulations
Bao, H., Wang, W., Sun, H. B., & Chen, J. Z. (2023) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2023.2165542 · Cited by 18
Identification of the first structurally validated covalent ligands of the small GTPase RAB27A
Jamshidiha, M., Lanyon‐Hogg, T., Sutherell, C. L., Craven, G. B., Tersa, M., Vita, E. D., Brustur, D., Pérez‐Dorado, I., Hassan, S., Petracca, R., et al. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00225b · Cited by 18
Diffusion Limit and the Reactivity/Affinity Conundrum: Implications for Optimization and Hit Finding for Irreversible Modulators
Srinivasan, B. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02863 · Cited by 19
DIAPH3 promotes the tumorigenesis of lung adenocarcinoma
Guo, X., He, W., Gao, E., & Ma, H. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.111662 · Cited by 18
Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors
Davies, C. W., Oh, A. J., Mroue, R., Steffek, M., Bruning, J. M., Xiao, Y., Feng, S., Jayakar, S., Chan, E., Arumugam, V., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01126-9 · Cited by 17
Current perspectives of KRAS in non-small cell lung cancer
Harris, E., & Thawani, R. (2024) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2024.101106 · Cited by 17
Repurposing drug molecule against SARS-Cov-2 (COVID-19) through molecular docking and dynamics: a quick approach to pick FDA-approved drugs
Farhat, N., & Khan, A. U. (2021) · Journal of Molecular Modeling · doi:10.1007/s00894-021-04923-w · Cited by 16
Allosteric Binding-Mediated Suppression on Activity of G12D KRAS Recognized via Markov State Model and Communication Pathway
Chen, J., Wang, J., Wang, W., Zhao, L., Jin, H., & Hu, G. (2026) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c07583 · Cited by 16
Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia
Chen, Y., Yin, Z., Westover, K. D., Zhou, Z., & Shu, L. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0504 · Cited by 15
Self-citation
Accelerating the Validation of Endogenous On-Target Engagement and In Cellulo Kinetic Assessment for Covalent Inhibitors of KRASG12C in Early Drug Discovery
Kantae, V., Polański, R., Lewis, H. J., Haider, A., Barratt, D. G., & Srinivasan, B. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00483 · Cited by 15
Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families
Li, L., Meyer, C., Zhou, Z.-W., Elmezayen, A., & Westover, K. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167626 · Cited by 14
Self-citation
Profiling Nascent Tumor Extracellular Vesicles via Metabolic Timestamping and Aptamer-Driven Specific Click Chemistry
Wu, Q., Zeng, Y., Wang, W., Liu, S., Huang, Y., Zhang, Y., Chen, X., You, Z., Zhang, C., Wang, T., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c01973 · Cited by 15
Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine
Şahin, İ. H., Saridogan, T., Ayasun, R., Syed, M. P., Gorantla, V. C., Malhotra, M. K., Thomas, R. A., Rhee, J. C., Zhang, J. Y., Hsu, D. J., et al. (2024) · JCO Oncology Practice · doi:10.1200/op.23.00787 · Cited by 13
Design of a Lead-Like Cysteine-Targeting Covalent Library and the Identification of Hits to Cys55 of Bfl-1
Lucas, S. C. C., Milbradt, A. G., Blackwell, J. H., Bonomo, S., Brierley, A., Cassar, D. J., Freeman, J., Hadfield, T. E., Morrill, L. A., Riemens, R., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00781 · Cited by 15
Discovery of Fulzerasib (GFH925) for the Treatment of KRAS G12C-Mutated Solid Tumors
Jiang, T., Lin, C., Le, S., Zhang, L., Liang, T., Cai, L., Lan, X., Ge, M., Liu, Z., He, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03183 · Cited by 14
Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant
Zhang, Z., Wang, X., Ye, J., Liu, H., Fang, J., Zhang, M., Li, Y., Huang, J., Zhang, D., Wang, J., et al. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00426 · Cited by 15
Mutant-Specific Targeting of Ras G12C Activity by Covalently Reacting Small Molecules
Goody, R. S., Müller, M. P., & Rauh, D. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.07.005 · Cited by 14
Identification of VVD-214/RO7589831, a Clinical-Stage, Covalent Allosteric Inhibitor of WRN Helicase for the Treatment of MSI-High Cancers
Kikuchi, S., Green, J. C., Rogness, D. C., Lam, B., Owyang, Z. A., Malmstrom, R. D., Tabatabaei, A., Snead, A. N., Hoffman, M. A., Bernard, S. M., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01805 · Cited by 15
Advanced technologies for screening and identifying covalent inhibitors
Guo, Y., Wen, S., Tong, A., & Wang, Y. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117833 · Cited by 11
The structure of KRAS G12C bound to divarasib highlights features of potent switch-II pocket engagement
Fernando, M. C., Craven, G. B., & Shokat, K. M. (2024) · Small GTPases · doi:10.1080/21541248.2025.2505441 · Cited by 12
Targeting a Novel KRAS Binding Site: Application of One-Component Stapling of Small (5–6-mer) Peptides
Fumagalli, G., Carbajo, R. J., Nissink, J. W. M., Tart, J., Dou, R., Thomas, A. P., & Spring, D. R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01334 · Cited by 12
Covalent Ligand Electrophiles Are Differentially Activated by Proximity Effects Which Govern Latent Protein Reactivity
Frankovich, T. V., McCann, H. M., Hoffman, K. S., & Rullo, A. F. (2025) · ACS Central Science · doi:10.1021/acscentsci.5c00699 · Cited by 10
Kinase signalling adaptation supports dysfunctional mitochondria in disease
Skalka, G., Tsakovska, M., & Murphy, D. J. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1354682 · Cited by 12
Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?
Fu, S., Ma, J., Cai, C., Tan, J., Deng, X., Shen, H., Zeng, S., Chen, Y., & Han, Y. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03444-1 · Cited by 11
Self-citation
Probing the KRas Switch II Groove by Fluorine NMR Spectroscopy
Peacock, D. M., Kelly, M. J. S., & Shokat, K. M. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00566 · Cited by 8
Covalent fragment mapping of KRasG12C revealed novel chemotypes with in vivo potency
Orgován, Z., Péczka, N., Petri, L., Ábrányi‐Balogh, P., Ranđelović, I., Tóth, S., Szakács, G., Nyíri, K., Vértessy, B. G., Pálfy, G., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115212 · Cited by 10
Exploitation of Proximity-Mediated Effects in Drug Discovery: An Update of Recent Research Highlights in Perturbing Pathogenic Proteins and Correlated Issues
Zhao, C., Wang, H., Zhan, W., Lv, X., & Ma, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00079 · Cited by 9
Contribution of Noncovalent Recognition and Reactivity to the Optimization of Covalent Inhibitors: A Case Study on KRasG12C
Péczka, N., Ranđelović, I., Orgován, Z., Csorba, N., Egyed, A., Petri, L., Ábrányi‐Balogh, P., Gadanecz, M., Perczel, A., Tóvári, J., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00217 · Cited by 10
Size-Dependent Target Engagement of Covalent Probes
Petri, L., Gabizon, R., Ferenczy, G. G., Péczka, N., Egyed, A., Ábrányi‐Balogh, P., Takács, T., & Keserű, G. M. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00017 · Cited by 10
Let K-Ras activate its own inhibitor
Statsyuk, A. V. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0066-0 · Cited by 9
Binding modes of the KRAS(G12C) inhibitors GDC-6036 and LY3537982 revealed by all atom molecular dynamics simulations
Leini, R., Kapp, J. N., Kopra, K., & Pantsar, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-07532-2 · Cited by 8
COOKIE-Pro: covalent inhibitor binding kinetics profiling on the proteome scale
Lin, H., Yang, B., Ding, L., Yang, Y., Holt, M. V., Jung, S. Y., Zhang, B., Wang, M. C., & Wang, J. (2025) · Nature Communications · doi:10.1038/s41467-025-63491-2 · Cited by 10

Authors: Hansen, R., Peters, U., Babbar, A., Chen, Y., Feng, J., Janes, M. R., Li, L.-S., Ren, P., Liu, Y., & Zarrinkar, P. P.
Affiliations: Wellspring Biosciences (United States) (US)
Kura Oncology (United States) (US)
Corresponding author: Zarrinkar, Patrick P.
ORCID: Peters, Ulf
Janes, Matthew R.
Li, Lian-Sheng
Ren, Pingda
Liu, Yi
Zarrinkar, Patrick P.
Venue: Nature Structural & Molecular Biology
Publisher: Springer Science and Business Media LLC
Published: 2018-05-14
Volume: 25
Issue: 6
Pages: 454-462
ISSN: 1545-9985 (ISSN-L)
1545-9993
DOI: 10.1038/s41594-018-0061-5
OpenAlex: W2800484366
Cited by: 153
References: 39
Citations by year: 2026: 14 · 2025: 18 · 2024: 20 · 2023: 16 · 2022: 20 · 2021: 15 · 2020: 25 · 2019: 19 · 2018: 5
FWCI: 6.22
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Structural & Molecular Biology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords: KRAS G12C, covalent inhibitors, undruggable targets, enzyme kinetics, small molecule inhibitors
MeSH terms: Animals, Catalysis, Cysteine, Humans, Kinetics, Mutation, Neoplasms, Protein Binding, Genes, ras, ras Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks